about
Management of osteoporosisRecognizing and treating secondary osteoporosisData sources on drug safety evaluation: a review of recent published meta-analyses.Role of teriparatide in treatment of glucocorticoid-induced osteoporosisA roadmap to the brittle bones of cystic fibrosis.Inhalational Steroids and Iatrogenic Cushing's SyndromeSystemic effects of inhaled corticosteroids: an overview.Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review.Medical treatment of vertebral osteoporosisFive year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoidsA two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country.Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based AnalysisThe risk/benefit of inhaled corticosteroids in chronic obstructive pulmonary disease.Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma.Glucocorticoid-induced osteoporosis and osteonecrosis.Glucocorticoid-induced osteoporosis: how best to avoid fractures.The Skeletal Effects of Inhaled Glucocorticoids.Spinal and paraspinal lesions: the role of stereotactic body radiotherapy.Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.Risk of adverse gastrointestinal events from inhaled corticosteroids.Bone involvement in exogenous hypercortisolism.Long-term therapy in COPD: any evidence of adverse effect on bone?Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores.Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case reportInterpretation and use of FRAX in clinical practice.Corticosteroid-induced osteoporosis: an update for dermatologists.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.Management of glucocorticoid-induced osteoporosis.Tiotropium for adults with inadequately controlled persistent asthma.Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool.Perceived stress and risk of any osteoporotic fracture.Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.Development and clinical gains of nurse-led medication monitoring profiles.Discriminative capacity of calcaneal quantitative ultrasound and of osteoporosis and fracture risk factors in postmenopausal women with osteoporotic fractures.Inhaled corticosteroids and hip fracture: a population-based case-control study.Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis?
P2860
Q24795473-D052B19E-6E80-4E20-B59E-985B727DB1FDQ28270738-FB75B0D0-4876-43AB-BAD4-E9FC491BAD07Q34057069-641A107B-7F45-4747-BCA9-9C7AAFA3D04FQ34235921-8694B373-0AE7-4C12-B819-A50BEE1BC06FQ34442832-2893FAE1-BBC8-48B2-B3FB-80E288DCE9CFQ35056151-B0F4A8D7-CB08-494D-A4C1-4B69C96BDD71Q35056155-BBEF2A69-BC90-48EF-9FEA-CD7623944D16Q35210556-E68D97B8-DF5A-4F37-89D4-3A39703B0C5BQ35299212-C9C5DADC-0C83-43E3-8D0F-6C9DB49E57BDQ35536952-6FE10D4B-EFAB-4872-9981-A10E0CC7F354Q35556027-C92242CF-8575-4522-BB5E-8A0F3B6C03C0Q35601856-447E6971-7DF7-4BE7-BE6F-AC3BD192180AQ35919546-0999AF55-F51B-4F4B-BEF4-0F1DDA83598CQ36045845-D6CC88DA-04B3-417A-8319-05B2B73C26BBQ36082007-20FB217E-95C3-4BC4-9565-3E92A3547AE4Q36145839-A122CA80-6898-4164-9400-ACC142694EEDQ36157622-E49877C1-965E-487E-9860-7634D3FA3996Q36443660-FD687614-EC92-4BA9-A536-23B2D5ED0A43Q36885279-F1B9F882-A052-4920-BB83-79540E3DA965Q36887077-8D1EE2AA-CDC3-4126-804F-9D9F659087F7Q37062092-152D7139-09DD-4E4A-BA5D-AF0887465881Q37111058-DECDC651-0611-442E-A2C5-6A73567DAB04Q37161922-AABCBDDB-8004-473F-8086-DEFA19AE75F3Q37408472-D4A22C3F-DC36-4CDE-AAC1-2F18541F646FQ37427052-AB362A2C-C9F8-4F9D-A823-07C4D616EDE8Q37567212-A91F6A76-E235-4E36-BE22-A958041A494CQ37903748-6E532DB0-88DD-4847-BA67-2154DE4216ECQ37990943-CDECA2B0-2F51-435E-825F-C09038264F6BQ37995500-53962D20-EE49-413A-A468-056FE6D13F00Q38033444-FC184FFD-CE20-4C08-9E68-76B4CB9ACBA2Q38074513-3BA5961E-832A-4538-8DD0-BEC968E3BA31Q38840402-79324070-E4B7-49EA-86C3-97A54A4676A2Q40087286-65250420-4845-4DA9-A6FA-536D9338EFDFQ42780846-C96DDE65-5441-46E4-B1EF-34F72B9E7841Q43288122-065E3568-A460-482D-93B0-D51D70D592C2Q44927006-3CCA2A11-8249-4A63-B923-A1C68E37027FQ45943734-69E5A453-AA5A-4D36-BB3D-D56B655A23B5Q46204637-D788F748-FB04-4E55-945D-1D2C54044A69Q50709815-DC4E4F21-6377-42A4-88E3-589D7883110BQ51581540-E992BCD8-0F9A-4684-91DE-A09ED058283B
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Use of inhaled corticosteroids and risk of fractures.
@en
Use of inhaled corticosteroids and risk of fractures.
@nl
type
label
Use of inhaled corticosteroids and risk of fractures.
@en
Use of inhaled corticosteroids and risk of fractures.
@nl
prefLabel
Use of inhaled corticosteroids and risk of fractures.
@en
Use of inhaled corticosteroids and risk of fractures.
@nl
P1476
Use of inhaled corticosteroids and risk of fractures
@en
P2093
H G Leufkens
P304
P356
10.1359/JBMR.2001.16.3.581
P577
2001-03-01T00:00:00Z